JP2002538180A - 妊娠能力を制御するための物質 - Google Patents
妊娠能力を制御するための物質Info
- Publication number
- JP2002538180A JP2002538180A JP2000602760A JP2000602760A JP2002538180A JP 2002538180 A JP2002538180 A JP 2002538180A JP 2000602760 A JP2000602760 A JP 2000602760A JP 2000602760 A JP2000602760 A JP 2000602760A JP 2002538180 A JP2002538180 A JP 2002538180A
- Authority
- JP
- Japan
- Prior art keywords
- lhop
- substance
- fertility
- tested
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title claims abstract description 46
- 230000035558 fertility Effects 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 29
- 230000001737 promoting effect Effects 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 34
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 210000001672 ovary Anatomy 0.000 description 19
- 102000009151 Luteinizing Hormone Human genes 0.000 description 16
- 108010073521 Luteinizing Hormone Proteins 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 229940040129 luteinizing hormone Drugs 0.000 description 16
- 230000035800 maturation Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 238000001952 enzyme assay Methods 0.000 description 9
- 230000016087 ovulation Effects 0.000 description 9
- 101100108551 Mus musculus Akr1b7 gene Proteins 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 102100026451 Aldo-keto reductase family 1 member B10 Human genes 0.000 description 5
- 108090000994 Catalytic RNA Proteins 0.000 description 5
- 102000053642 Catalytic RNA Human genes 0.000 description 5
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 101000718041 Homo sapiens Aldo-keto reductase family 1 member B10 Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 108091092562 ribozyme Proteins 0.000 description 5
- 102000005602 Aldo-Keto Reductases Human genes 0.000 description 4
- 108010084469 Aldo-Keto Reductases Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000004720 fertilization Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000010009 steroidogenesis Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 210000001177 vas deferen Anatomy 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 150000003515 testosterones Chemical class 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 108010053423 ADP-ribosylation factor related proteins Proteins 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010061452 Complication of pregnancy Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000687 effect on sperms Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229940124566 female contraceptive agent Drugs 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical group OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000005121 nitriding Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000012113 pregnancy disease Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Reproductive Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19910394.1 | 1999-03-03 | ||
| DE19910394A DE19910394A1 (de) | 1999-03-03 | 1999-03-03 | Substanzen für die Fertilitätskontrolle |
| PCT/EP2000/001733 WO2000052148A2 (fr) | 1999-03-03 | 2000-03-02 | Substances destinees au controle de fertilite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002538180A true JP2002538180A (ja) | 2002-11-12 |
Family
ID=7900280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000602760A Pending JP2002538180A (ja) | 1999-03-03 | 2000-03-02 | 妊娠能力を制御するための物質 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1157099A2 (fr) |
| JP (1) | JP2002538180A (fr) |
| AU (1) | AU3284500A (fr) |
| DE (1) | DE19910394A1 (fr) |
| WO (1) | WO2000052148A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10152598A1 (de) * | 2001-10-19 | 2003-05-22 | Schering Ag | ARL-2-für die Fertilitätskontrolle |
| WO2003046165A1 (fr) * | 2001-11-26 | 2003-06-05 | Bayer Healthcare Ag | Régulation de la protéine humaine de type aldose réductase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2680229B2 (ja) * | 1992-02-12 | 1997-11-19 | 三菱瓦斯化学 株式会社 | 人アルドース還元酵素の測定方法 |
| US5563059A (en) * | 1993-02-23 | 1996-10-08 | Genentech, Inc. | Use of human inhibin and human activin to increase the number of mature primate oocytes |
| ATE314392T1 (de) * | 1994-02-18 | 2006-01-15 | Univ Washington | Einzelketten-gonadotropin |
-
1999
- 1999-03-03 DE DE19910394A patent/DE19910394A1/de not_active Withdrawn
-
2000
- 2000-03-02 AU AU32845/00A patent/AU3284500A/en not_active Abandoned
- 2000-03-02 WO PCT/EP2000/001733 patent/WO2000052148A2/fr not_active Application Discontinuation
- 2000-03-02 JP JP2000602760A patent/JP2002538180A/ja active Pending
- 2000-03-02 EP EP00910742A patent/EP1157099A2/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000052148A2 (fr) | 2000-09-08 |
| DE19910394A1 (de) | 2000-09-07 |
| EP1157099A2 (fr) | 2001-11-28 |
| AU3284500A (en) | 2000-09-21 |
| WO2000052148A9 (fr) | 2001-09-13 |
| WO2000052148A3 (fr) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fehrenbach et al. | Up-regulated expression of the receptor for advanced glycation end products in cultured rat hepatic stellate cells during transdifferentiation to myofibroblasts | |
| CN105324123B (zh) | 激素分泌调节剂、包含该调节剂的组合物、和利用其控制激素分泌的方法 | |
| JP2002508770A (ja) | Ｕｃｐ−２の調節を変化させることが可能な薬剤の使用および肥満に対抗する可能性のある薬剤のスクリーニング方法 | |
| KR20070112761A (ko) | 부신피질 자극 호르몬 유사체 및 관련 방법 | |
| JP2002537348A (ja) | 不妊症の治療 | |
| CN107375910B (zh) | PTHrP在制备治疗男性性腺功能低下综合征中的应用 | |
| Bigazzi et al. | Is human decidua a specialized endocrine organ? | |
| JP2016183147A (ja) | 挫瘡およびその他の状態を治療するためのビスファチン治療薬 | |
| Friedrich et al. | Up-regulation of the human serum and glucocorticoid-dependent kinase 1 in glomerulonephritis | |
| JP2002515445A (ja) | 細胞毒性活性を有する医薬品調製のためのｈｍｇ蛋白質の使用 | |
| Han et al. | Expression and regulation of inhibitor of DNA binding proteins ID1, ID2, ID3, and ID4 at the maternal-conceptus interface in pigs | |
| US5830848A (en) | Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy | |
| Lee et al. | Expression of components of the insulin-like growth factor system in pig mammary glands and serum during pregnancy and pseudopregnancy: effects of oestrogen | |
| Morash et al. | The regulation of leptin gene expression in the C6 glioblastoma cell line | |
| RU2727142C2 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| Kubota et al. | Insulin-like growth factor II in follicular fluid of the patients with in vitro fertilization and embryo transfer | |
| Silva et al. | Effect of the duration of estradiol priming prior to progesterone administration on endometrial gene expression in anestrous mares | |
| KUNG et al. | Interferon-γ inhibits thyrotropin-induced thyroglobulin gene transcription in cultured human thyrocytes | |
| JP2002538180A (ja) | 妊娠能力を制御するための物質 | |
| Matthews et al. | Levels of pro-opiomelanocortin and prolactin mRNA in the fetal sheep pituitary following hypoxaemia and glucocorticoid treatment in late gestation | |
| Pradeep et al. | Protective effect of cardiomyocyte-specific prolyl-4-hydroxylase 2 inhibition on ischemic injury in a mouse MI model | |
| Lipton | MSH in CNS control of fever and its influence on inflammation/immune responses | |
| CN114426573B (zh) | 一种Nur77磷酸化衍生肽及其在制备促进胚胎植入的药物中的应用 | |
| Green et al. | Molecular cloning of spermidine/spermine N1-acetyltransferase from the periimplantation porcine uterus by messenger ribonucleic acid differential display: temporal and conceptus-modulated gene expression | |
| MXPA04002125A (es) | Uso de la hl en la hiperestimulacion ovarica controlada. |